Table of contents
- Trial overview
- Who is being studied
- What is being compared
- Study phase and design
- Main outcome being measured
- What the results may mean
Trial overview
The available trial data show one authorised study of TROFOLASTAT in people with prostate cancer.[1] This study is called PROSTAMIP and is a comparative, prospective, randomized trial for primary prostate cancer staging.[1]
The study is looking at whether the experimental imaging arm can detect local lymph node metastases better than the control arm.[1] In simple terms, the researchers want to know which scan is better at finding cancer spread to nearby lymph nodes.[1]
Who is being studied
The trial targets people with prostate cancer who need imaging for staging.[1] Staging means checking how far the cancer has spread in the body.[1]
The planned enrollment is 320 participants.[1] This size allows the researchers to compare the imaging groups in a larger patient group.[1]
What is being compared
The study compares three imaging-related options listed in the trial data: 18F-PSMA-1007, Pylclari, and 99mTc-MIP-1404.[1] The brief summary says the experimental arm uses 99mTc-MIP-1404 SPECT/CT, while the control arm uses ce-wbCT.[1]
SPECT/CT is an imaging test that combines two scan methods to help show where disease may be found.[1] The trial is testing whether the experimental scan gives better staging information than the control scan.[1]
Study phase and design
This is a Phase 4 study.[1] Phase 4 studies are later-stage trials, often used to compare how a test performs in clinical practice.[1]
The study type is interventional, which means the researchers assign participants to study groups rather than only observing them.[1] The title also says the trial is prospective and randomized, meaning people are followed forward in time and placed into groups by chance.[1]
Main outcome being measured
The primary outcome is the proportion of subjects with local lymph node metastases in the control and experimental arms, as read by the study readers.[1] A primary outcome is the main result the trial is designed to measure.[1]
This outcome is important because it shows how often each imaging method finds nearby lymph node spread.[1] The brief summary states that the experimental arm is expected to be superior in detecting these metastases compared with the control arm.[1]
What the results may mean
If the experimental imaging approach finds more local lymph node metastases, it may help doctors stage prostate cancer more accurately.[1] Better staging can support more informed treatment planning because it gives a clearer picture of disease spread.[1]
At this stage, the trial data only describe the study aim and design, not final results.[1] So the main focus is on comparing imaging performance in prostate cancer, not on treatment outcomes.[1]
